Optimize Your Workflow with Advanced Infectious Disease TestingFuture-proof your lab with flexible consolidation, a growing test menu, and high-throughput efficiency.
Consolidate assays into a single, intelligent system
Infectious diseases (ID) are both dangerous and unpredictable, making accurate screening and detection necessary for improving patient outcomes and safeguarding public health. The ever-evolving infectious disease landscape leaves many laboratories seeking great flexibility, efficiency and control.
Today, there’s a more advanced solution available: the Atellica infectious disease assay portfolio, powered by a SMART algorithm and proprietary Acridinium Ester (AE) technology that optimizes workflows, enhances performance, and consolidates a comprehensive and growing menu onto a single, intelligent system engineered with built-in automation.
Laboratories can process more samples with fewer touchpoints, achieve faster turnaround times, and reduce staff exposure to biohazards. High-performance ID assays deliver enhanced precision empowering clinicians to make more confident care decisions.
Engineered to adapt seamlessly to short-term fluctuations and long-term shifts in testing demand, the Atellica infectious disease assays equip laboratories to meet today’s challenges and tomorrow’s demands with confidence.
From HIV and hepatitis to ToRCH infections, syphilis, and procalcitonin, these assays are part of the Atellica infectious disease portfolio—providing laboratories with trusted infectious disease diagnostic solutions across a wide range of clinical needs.
The landscape of infectious disease testing is evolving
Atellica IM Assay Menu
Evidence
"Challenges for the modern lab can, in part, be addressed by innovative analyzer technology design, such as the Atellica IM, where a dual ring design allows assay menu consolidation without compromising throughput and STAT turnaround time (TAT) results delivery."
Zuckerberg San Francisco General Hospital
CA, USA
White Paper
Real World Assessment of the Impact of Infectious Disease Assays on Workflow Capabilities of Atellica IM Analyzer
This white paper provides proof of principle by examining the impact of having increasingly higher percentages of ID assays, including longer assays, on delivery times of the high-sensitivity cardiac troponin assay. The data is especially powerful as over a million data points were collected across analyzers in a large number of labs.
Learn more about how you can enhance your infectious disease testing to a consolidated platform without sacrificing throughput.